Novavax Inc vs Abbvie Inc.
NVAX vs ABBV — side-by-side comparison from reported financials. NVAX leads 4, ABBV leads 6 of 10 comparable metrics.
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | NVAX | ABBV |
|---|---|---|
| Price | $12.73 | $276.43 |
| Market cap | $2.10B | $488B |
| Revenue (TTM) | $414M | $64.4B |
| Revenue growth | -17.2% | +1.8% |
| Net margin | -59.9% | 9.8% |
| Free cash flow | -$42.8M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +48.2% | +19.8% |
| P/E | 4.8 | 77.4 |
| P/E vs own history (cheap-side %) | 29% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 283% | 96% |
| Altman Z-score | -5.14 | 2.33 |
| CV checks passed | 4 of 10 | 9 of 10 |
| Employees | 749 | 57,000 |
Full résumé-style profiles: NVAX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.